title: [Results of treatment of primary metastatic Ewing sarcoma. A retrospective analysis of 48 patients].
abstract: The clinical presentation of the disease and the results of treatment in 48 patients with metastases at diagnosis of Ewing's sarcoma, entered into the Cooperative Ewing's Sarcoma Studies (CESS) 1981 and 1986 of the German Society of Pediatric Oncology (GPO), were analysed. The period of observation ranged from 1 to 82 months, the median relapse-free time was 26 months. There was a male predominance of 35 to 13, which was even more pronounced in patients older than 15 years. The predominant localization of the primary tumor was the pelvic region, followed by the extremities, the chest wall, and the spine. The most common site of primary metastases were the lungs, followed by bone and bone marrow. Nine patients presented with combined metastases. The disease-free survival according to Kaplan-Meier life-table analysis was 18% after 7 years. Best results were obtained in patients with pulmonary metastases only, who underwent surgical resection of the primary tumor and received radiation to the lungs. Without bone marrow transplantation the prognosis of patients with bone metastases was extremely poor.
authors.affiliation: Universitätskinderkliniken Düsseldorf.
authors.forename: R
authors.initials: R
authors.lastname: Wessalowski
authors.forename: H
authors.initials: H
authors.lastname: Jürgens
authors.forename: H
authors.initials: H
authors.lastname: Bodenstein
authors.forename: W
authors.initials: W
authors.lastname: Brandeis
authors.forename: P
authors.initials: P
authors.lastname: Gutjahr
authors.forename: W
authors.initials: W
authors.lastname: Havers
authors.forename: M L
authors.initials: ML
authors.lastname: Huckels-Klasen
authors.forename: R
authors.initials: R
authors.lastname: Kotz
authors.forename: J
authors.initials: J
authors.lastname: Kühl
authors.forename: M
authors.initials: M
authors.lastname: Salzer-Kuntschik
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D001859:Bone Neoplasms / Q000188:drug therapy*; D002648:Child; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D003609:Dactinomycin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008297:Male; D009362:Neoplasm Metastasis; D012189:Retrospective Studies; D012512:Sarcoma, Ewing / Q000188:drug therapy*; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D003609:Dactinomycin; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D007069:Ifosfamide
vernacular_title: Behandlungsergebnisse beim primär metastasierten Ewing-Sarkom. Eine retrospektive Analyse von 48 Patienten.